Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cody Ashby

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Journal of Hematology & Oncology|August 9, 2020
The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSamrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, et al.
Haematologica|November 20, 2023
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myelomaSilvia Marino, Daniela N Petrusca, Ryan T Bishop, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Oncotarget|February 19, 2019
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of <i>TP53</i>Cody Ashby, Ruslana G Tytarenko, Yan Wang, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
The Journal of Clinical Investigation|June 1, 2021
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignanciesCan Li, Jiliang Xia, Reinaldo Franqui-Machin, et al.
Cancer Biomarkers : Section a of Disease Markers|June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myelomaFumou Sun, Yan Cheng, Catherine Ma, et al.
Blood Cancer Journal|October 16, 2025
Equal survival for Black Americans with multiple myeloma when appropriately matched to White AmericansDavid E Mery, Guido Tricot, Samer Al Hadidi, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Haematologica|November 28, 2024
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myelomaAric Anloague, Hayley M Sabol, Japneet Kaur, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Journal of Hematology & Oncology|August 9, 2020
The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSamrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, et al.
Haematologica|November 20, 2023
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myelomaSilvia Marino, Daniela N Petrusca, Ryan T Bishop, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Oncotarget|February 19, 2019
Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of <i>TP53</i>Cody Ashby, Ruslana G Tytarenko, Yan Wang, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
The Journal of Clinical Investigation|June 1, 2021
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignanciesCan Li, Jiliang Xia, Reinaldo Franqui-Machin, et al.
Cancer Biomarkers : Section a of Disease Markers|June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myelomaFumou Sun, Yan Cheng, Catherine Ma, et al.
Blood Cancer Journal|October 16, 2025
Equal survival for Black Americans with multiple myeloma when appropriately matched to White AmericansDavid E Mery, Guido Tricot, Samer Al Hadidi, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Haematologica|November 28, 2024
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myelomaAric Anloague, Hayley M Sabol, Japneet Kaur, et al.
Pageof 6